Tracking semaglutide's approved indications across jurisdictions, dated

Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did.

Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it.

semaglutide, monoisotopic mass near 4113.6 Da, 24 weeks of my own notes, and 7 lots from 4 suppliers with a purity figure on each. That is the whole basis of what follows.

What I want checked is the reasoning I have built on top of it, not the figures themselves.

Where I part company with the opening post, and it is a narrow parting.

Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary.

That matches what I was told, which is not the same as knowing it.

Post #10 answers the question as asked. The question underneath it is different.

The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.

If this contradicts something upthread, the upthread version may well be the better one.

Narrowing post #14, because the general version has more than one answer.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.